Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response

The response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered...

ver descrição completa

Detalhes bibliográficos
Autores: Herrero-Fernández, Inés, Pacheco, Yolanda M., Genebat, Miguel, Rodríguez-Méndez, M. del Mar, Lozano-Domínguez, María del Carmen, Polaino, María José, Rosado-Sánchez, Isaac, Tarancón-Díez, Laura, Muñoz-Fernández, María Ángeles, Ruiz-Mateos, Ezequiel, Leal, Manuel
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2018
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/182762
Acesso em linha:http://hdl.handle.net/10261/182762
Access Level:acceso abierto
Palavra-chave:Maraviroc
Vaccine
HIV infection
Combined antiretroviral treatment
Hepatitis A virus
Hepatitis B virus
id ES_f0e37aa2575c2fe97cb7cd0f7c95122b
oai_identifier_str oai:digital.csic.es:10261/182762
network_acronym_str ES
network_name_str España
repository_id_str
spelling Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine ResponseHerrero-Fernández, InésPacheco, Yolanda M.Genebat, MiguelRodríguez-Méndez, M. del MarLozano-Domínguez, María del CarmenPolaino, María JoséRosado-Sánchez, IsaacTarancón-Díez, LauraMuñoz-Fernández, María ÁngelesRuiz-Mateos, EzequielLeal, ManuelMaravirocVaccineHIV infectionCombined antiretroviral treatmentHepatitis A virusHepatitis B virusThe response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered the HBV vaccine. The final response, the early response, and the maintenance of the response were assessed. An anti-HBs titer of >10 mIU/ml was considered a positive response. A subgroup of subjects was simultaneously vaccinated against hepatitis A virus (HAV). Lineal regression analyses were performed to determine demographic, clinical, and immunological factors associated with the anti-HBs titer. Vaccine response was achieved in 90% of the subjects. After 1 year, 81% maintained protective titers. Only simultaneous HAV vaccination was independently associated with the magnitude of the response in anti-HBs titers, with a P value of 0.045 and a regression coefficient (B) [95% confident interval (CI)] of 236 [5 to 468]. In subjects ≤50 years old (n = 42), MVC-cART was independently associated with the magnitude of the response (P = 0.009; B [95% CI], 297 [79 to 516]) together with previous vaccination and simultaneous HAV vaccination. High rates of HBV vaccine response can be achieved by revaccination, simultaneous HAV vaccination, and administration of cARTs including MVC. MVC may be considered for future vaccination protocols in patients on suppressive cART.This study was funded by an investigator-initiated research grant from ViiV Healthcare S.L. (grant number 205644) and by grants from the Fondo de Investigación Sanitaria (FIS; PI14/01693; PI16/01863), cofunded by Fondos Europeos para el Desarrollo Regional (FEDER) and the Junta de Andalucía, Consejería de Economía, Innovación, Ciencia y Empleo (Proyecto de Investigación de Excelencia; CTS2593). The Spanish AIDS Research Network of Excellence also supported this study (RD16/0025/0019). E.R.-M. and Y.M.P. were supported by the Fondo de Investigación Sanitaria through the ‘Miguel Servet’ programs (CPII014/00025 and CPII13/00037, respectively). Y.M.P. was supported by the Consejería de Salud y Bienestar Social of Junta de Andalucía through the ‘Nicolás Monardes’ program (C-0010/13). L.T.-D. was supported by Instituto de Salud Carlos III (PFIS program; FI00/00431).Peer reviewedAmerican Society for MicrobiologyViiV HealthcareInstituto de Salud Carlos IIIEuropean CommissionJunta de AndalucíaRed Española de Investigación en SIDAConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]201920192018info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Postprintinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttp://hdl.handle.net/10261/182762reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1128/AAC.02050-17Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/1827622026-05-22T06:33:51Z
dc.title.none.fl_str_mv Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
title Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
spellingShingle Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
Herrero-Fernández, Inés
Maraviroc
Vaccine
HIV infection
Combined antiretroviral treatment
Hepatitis A virus
Hepatitis B virus
title_short Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
title_full Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
title_fullStr Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
title_full_unstemmed Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
title_sort Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
dc.creator.none.fl_str_mv Herrero-Fernández, Inés
Pacheco, Yolanda M.
Genebat, Miguel
Rodríguez-Méndez, M. del Mar
Lozano-Domínguez, María del Carmen
Polaino, María José
Rosado-Sánchez, Isaac
Tarancón-Díez, Laura
Muñoz-Fernández, María Ángeles
Ruiz-Mateos, Ezequiel
Leal, Manuel
author Herrero-Fernández, Inés
author_facet Herrero-Fernández, Inés
Pacheco, Yolanda M.
Genebat, Miguel
Rodríguez-Méndez, M. del Mar
Lozano-Domínguez, María del Carmen
Polaino, María José
Rosado-Sánchez, Isaac
Tarancón-Díez, Laura
Muñoz-Fernández, María Ángeles
Ruiz-Mateos, Ezequiel
Leal, Manuel
author_role author
author2 Pacheco, Yolanda M.
Genebat, Miguel
Rodríguez-Méndez, M. del Mar
Lozano-Domínguez, María del Carmen
Polaino, María José
Rosado-Sánchez, Isaac
Tarancón-Díez, Laura
Muñoz-Fernández, María Ángeles
Ruiz-Mateos, Ezequiel
Leal, Manuel
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv ViiV Healthcare
Instituto de Salud Carlos III
European Commission
Junta de Andalucía
Red Española de Investigación en SIDA
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Maraviroc
Vaccine
HIV infection
Combined antiretroviral treatment
Hepatitis A virus
Hepatitis B virus
topic Maraviroc
Vaccine
HIV infection
Combined antiretroviral treatment
Hepatitis A virus
Hepatitis B virus
description The response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered the HBV vaccine. The final response, the early response, and the maintenance of the response were assessed. An anti-HBs titer of >10 mIU/ml was considered a positive response. A subgroup of subjects was simultaneously vaccinated against hepatitis A virus (HAV). Lineal regression analyses were performed to determine demographic, clinical, and immunological factors associated with the anti-HBs titer. Vaccine response was achieved in 90% of the subjects. After 1 year, 81% maintained protective titers. Only simultaneous HAV vaccination was independently associated with the magnitude of the response in anti-HBs titers, with a P value of 0.045 and a regression coefficient (B) [95% confident interval (CI)] of 236 [5 to 468]. In subjects ≤50 years old (n = 42), MVC-cART was independently associated with the magnitude of the response (P = 0.009; B [95% CI], 297 [79 to 516]) together with previous vaccination and simultaneous HAV vaccination. High rates of HBV vaccine response can be achieved by revaccination, simultaneous HAV vaccination, and administration of cARTs including MVC. MVC may be considered for future vaccination protocols in patients on suppressive cART.
publishDate 2018
dc.date.none.fl_str_mv 2018
2019
2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Postprint
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/182762
url http://hdl.handle.net/10261/182762
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1128/AAC.02050-17
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424050243108864
score 15,811543

Registos relacionados